{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T06:15:08Z","timestamp":1783318508783,"version":"3.54.6"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A growing share of oncology drugs receive FDA approval via expedited pathways based on interim RCT analyses, leaving safety data relatively immature at approval. Whether the relative toxicity of approved therapeutics shifts as trials mature remains unquantified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Phase II\u2013III RCTs underpinning FDA oncology approvals from 2006 to 2025 were eligible if both the approval-stage dataset and at least one subsequent publication reported grade \u22653 AEs or serious AEs (SAEs). For each trial, experimental-versus-control odds ratios (ORs) were computed at both timepoints, with within-trial change indexed by the ratio of odds ratios (ROR), defined as the updated OR divided by the initial OR (ROR\u202f&amp;gt;\u202f1 indicating greater experimental-arm toxicity after maturation). Random-effects meta-analyses pooled log-scale estimates; meta-regression explored effect modifiers and sources of heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety-nine RCTs met eligibility and, after splitting seven three-arm trials, yielded 106 pairwise comparisons (103 for grade \u22653 AEs; 70 for SAEs). Pooled OR for grade \u22653 AEs rose from 1.09 (95% CI, 0.93\u20131.22) to 1.29 (1.03\u20131.43); meta-analytic ROR showed a statistically significant increase at 1.095 (1.038\u20131.156;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f12.8%), with 78\/103 comparisons shifting toward greater experimental toxicity. For SAEs, pooled OR rose from 1.32 (1.21\u20131.42) to 1.45 (1.27\u20131.59); ROR was 1.06 (0.97\u20131.17;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.22;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f46.8%), directionally concordant but not statistically significant, with upward shifts in 49\/70 comparisons. Amplification was most evident for all-cause events and in crossover-permitted, blinded, medium-sized, and later-line trials, and in lung, prostate, and breast cancer. RORs declined across more recent cohorts (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u202f=\u202f\u22120.027,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.009 for SAEs); larger enrollment, longer follow-up, blinded designs, and all-cause ascertainment predicted greater drift, while mature initial follow-up and metastatic settings attenuated it. We derived an exploratory Toxicity Drift Predictor to estimate post-approval ROR of SAEs from pre-approval trial features.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FDA-approved oncology therapeutics show systematic post-approval increases in relative toxicity, most pronounced for all-cause events and designs prolonging differential exposure. Though attenuated for recent agents, the approval-stage safety profile represents a lower-bound estimate of long-term comparative harm, supporting evidence-maturity\u2013based dynamic oversight with predefined safety-update milestones and structured surveillance of delayed toxicities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1882548","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:36:53Z","timestamp":1783316213000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal changes in the relative toxicity of FDA-approved oncology therapeutics: evidence from paired initial and updated RCT reports"],"prefix":"10.3389","volume":"14","author":[{"given":"Weiqiang","family":"Song","sequence":"first","affiliation":[{"name":"Department of Urology, Hebei Petrochina Central Hospital","place":["Langfang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Hebei Petrochina Central Hospital","place":["Langfang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangpeng","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Public Health, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhao","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Hebei Petrochina Central Hospital","place":["Langfang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/ijc.34473","article-title":"The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020","volume":"152","author":"Gloy","year":"2023","journal-title":"Int J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMp2116863","article-title":"The wild west of checkpoint inhibitor development","volume":"386","author":"Beaver","year":"2022","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.2024.2396","article-title":"Clinical benefit and regulatory outcomes of Cancer drugs receiving accelerated approval","volume":"331","author":"Liu","year":"2024","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1740774518770648","article-title":"The US Food and Drug Administration's expedited approval programs: evidentiary standards, regulatory trade-offs, and potential improvements","volume":"15","author":"Wallach","year":"2018","journal-title":"Clin Trials"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1001\/jama.2017.5150","article-title":"Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010","volume":"317","author":"Downing","year":"2017","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The drug-dosing conundrum in oncology - when less is more","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/OTT.S23273","article-title":"Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment","volume":"5","author":"Gr\u00fcnwald","year":"2012","journal-title":"Onco Targets Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/1078-0432.CCR-21-2275","article-title":"Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors","volume":"28","author":"Palmer","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1200\/JCO.2017.77.1592","article-title":"Efficacy, safety, and regulatory approval of Food and Drug Administration-designated breakthrough and nonbreakthrough Cancer medicines","volume":"36","author":"Hwang","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"100364","DOI":"10.1016\/j.jcpo.2022.100364","article-title":"FDA validation of surrogate endpoints in oncology: 2005-2022","volume":"34","author":"Walia","year":"2022","journal-title":"J Cancer Policy"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"l5221","DOI":"10.1136\/bmj.l5221","article-title":"Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European medicines agency, 2014-16: cross sectional analysis","volume":"366","author":"Naci","year":"2019","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2011.40.3824","article-title":"The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs","volume":"30","author":"Niraula","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00228-025-03960-1","article-title":"Safety of immune checkpoint inhibitors: a systematic review of disproportionality analysis studies","volume":"82","author":"Rathod","year":"2026","journal-title":"Eur J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"djx187","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world data for clinical evidence generation in oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.critrevonc.2019.04.008","article-title":"Efficacy and safety of combination immunotherapy for malignant solid tumors: a systematic review and meta-analysis","volume":"138","author":"Wei","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref24","first-page":"14651858","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Chandler","year":"2019"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1200\/JCO.2015.64.2488","article-title":"Comparison of treatment effects measured by the Hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials","volume":"34","author":"Trinquart","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/978-1-4757-3466-9_16","volume-title":"Applied Statistics in the Pharmaceutical Industry","author":"O\u2019Rourke","year":"2001"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s11135-006-9018-6","article-title":"A caution regarding rules of thumb for variance inflation factors","volume":"41","author":"O\u2019brien","year":"2007","journal-title":"Qual Quant"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1056\/NEJMp2104846","article-title":"\"dangling\" accelerated approvals in oncology","volume":"384","author":"Beaver","year":"2021","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of Cancer drugs receiving accelerated approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1016\/s2352-3026(18)30051-6","volume":"5","author":"Thanarajasingam","year":"2018","journal-title":"Lancet Haematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the randomized clinical trial in the era of precision oncology","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in Cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","article-title":"djuvant endocrine therapy in patients with breast cancer","volume":"22","author":"Franzoi","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"101455","DOI":"10.1016\/j.lanepe.2025.101455","article-title":"Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies","volume":"58","author":"Jourdain","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European haematology association (EHA)","volume":"33","author":"Hayden","year":"2021","journal-title":"Ann Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.15420\/ecr.2022.63","article-title":"The 2022 European Society of Cardiology Cardio-oncology Guidelines in focus","volume":"18","author":"Gent","year":"2023","journal-title":"Eur Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/s1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"j3837","DOI":"10.1136\/bmj.j3837","article-title":"Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study","volume":"358","author":"Mostaghim","year":"2017","journal-title":"BMJ"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/01947648.2013.800797","article-title":"Post-marketing surveillance of prescription drug safety: past, present, and future","volume":"34","author":"Chen","year":"2013","journal-title":"J Leg Med"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1882548\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:36:55Z","timestamp":1783316215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1882548\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":44,"alternative-id":["10.3389\/fpubh.2026.1882548"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1882548","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1882548"}}